The effectiveness of computerized cognitive training program for older adults with mild cognitive impairment and early dementia

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

December 23, 2021

Last Updated

2 years ago

Study Type

Interventional Study

Sex

All

Sponsor

•1\. Subjects diagnosed with mild cognitive impairment according to Petersen’s criteria (Petersen et al., 1999\) or early stage of major neurocognitive disorder according to DSM\-5 (American Psychiatric Association, 2013\)
•2\. Korean male or female over 60 years of age
•3\. Subjects with Clinical dementia rating global scale \= 1
•4\. Subjects whose existing treatment (medication or face\-to\-face treatment) can be confirmed (existing treatment itself is irrelevant)
•5\. Subjects for whom no other structural causes of cognitive decline were found in brain MRI
•6\. After hearing and fully understanding the detailed explanation of this clinical trial, the subject voluntarily decided to participate and signed the consent form to comply with the precautions.

•1\. Subjects with mental illness other than mild cognitive impairment and early Alzheimer's disease (schizophrenia, bipolar disorder, depression, etc.)
•2\. Subjects diagnosed with or accompanied by cognitive decline due to other degenerative brain diseases, infections of the central nervous system (HIV, syphilis, etc.), head trauma, Creutzfeld\-Jacob disease, Pick's disease, Huntington's disease, and Parkinson's disease
•3\. Subjects diagnosed with vascular dementia according to DSM\-5 (American Psychiatric Association, 2013\) criteria
•4\. Subjects with a history of stroke within 1 year of participating in the trial
•5\. Subjects who have participated in other treatment studies, including drugs, within 3 months before the start of the clinical trial (week 0\)
•6\. Those who cannot undergo tests (e.g. fMRI) conducted during the clinical trial period
•7\. Cancer patients (systemic cancer including brain tumor)
•8\. Drug/alcohol abuser
•9\. Other subjects deemed unsuitable by researchers to participate in clinical trials